[1] 刘丽,季婷婷,戴淑娟,等.血栓性疾病的药物治疗研究进展[J].齐齐哈尔医学院学报,2018,39(23): 2807-2808. [2] FURIE B,FLAUMENHAFT R.Thiol isomerases in thrombus formation [J].Circ Res,2014,114(7): 1162-1173. [3] 刘莅欣,胡桃红.血栓性疾病抗栓治疗的研究进展[J].中国临床医生,2013,41(5): 15-17. [4] 徐可.冠心病患者基因多态性、氯吡格雷反应性及临床预后的相关性研究[D].南京:南京医科大学,2018. [5] 梅丹,都丽萍,刘昌伟.基因多态性与华法林个体化用药[J].中华外科杂志,2016,54(2): 144-147. [6] GRAHAM B R,MENON B K.Clopidogrel load reduces emboli in carotid artery stenosis with free-floating thrombus [J].Can J Neurol Sci,2017,44(5): 594-596. [7] 张琳,王丹.氯吡格雷基因检测的临床应用分析[J].世界最新医学信息文摘,2018,18(76): 175. [8] TAN S S N,FONG A Y Y,MEJIN M,et al.Association of CYP2C19*2 polymorphism with clopidogrel response and 1-year major adverse cardiovascular events in a multiethnic population with drug-eluting stents [J].Pharmacogenomics,2017,18(13): 1225-1239. [9] LIU R,ZHOU Z Y,CHEN Y B,et al.Associations of CYP3A4,NR1I2,CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke [J].Acta Phamaco Sin,2016,37(7): 882-888. [10] FLORA D R,RETTIE A E,BRUNDAGE R C,et al.CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites [J].J Clin Pharmacol,2017,57(3): 382-393. [11] SHENDRE A,BROWN T M,LIU N,et al.Race-specific influence of CYP4F2 on dose and risk of hemorrhage among warfarin users [J].Pharmacotherapy,2016,36(3): 263-272. [12] GEMMATI D,BURINI F,TALARICO A,et al.The active metabolite of warfarin (3'-Hydroxywarfarin) and correlation with INR,warfarin and drug weekly dosage in patients under oral anticoagulant therapy: A pharmacogenetics study [J].PLoS One,2016,11(9): e0162084. [13] KRISHNA KUMAR D,SHEWADE D G,LORIOT M A,et al.Effect of CYP2C9,VKORC1,CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population [J].Eur J Clin Pharmacol,2014,70(1): 47-56. [14] WANG J.From DNA biosensors to gene chips [J].Nucleic Acids Res,2000,28(16): 3011-3016. [15] ORTEL T L,ERKAN D,KITCHENS C S.How I treat catastrophic thrombotic syndromes [J].Blood,2015,126(11): 1285-1293. [16] KAZUI M,NISHIYA Y,ISHIZUKA T,et al.Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite [J].Drug Metab Dispos,2010,38(1): 92-99. [17] SAIZ-RODRIGUEZ M,ROMERO-PALACIAN D,VILLALOBOS-VILDA C,et al.Influence of CYP2C19 phenotype on the effect of clopidogrel in patients undergoing a percutaneous neurointervention procedure [J].Clin Pharmacol Ther,2019,105(3): 661-671. [18] ZHUO Z L,XIAN H P,LONG Y,et al.Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients [J].Anatol J Cardiol,2018,19(2): 123-129. [19] HOLMES M V,PEREL P,SHAH T,et al.CYP2C19 genotype,clopidogrel metabolism,platelet function,and cardiovascular events: a systematic review and meta-analysis [J].JAMA,2011,306(24): 2704-2714. [20] DEAN L.Warfarin therapy and the genotypes CYP2C9 and VKORC1[J].Med Gene Summ,2012,2: 257-263. [21] KULMYRZAEVA N,TATARUNAS V,SKIPSKIS V,et al. Gene polymorphism of CYP2C19*2,*3 and CYP3A4* 1B and early stent thrombosis: case reports and literature review [J].Pers Med,2016,13(5): 423-428. [22] GONZALEZ DELLA VALLE A,KHAKHARIA S,GLUECK C J,et al.VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study [J].Clin Orthop Relat R,2009,467(7): 1773-1780. [23] 徐晓丽,林娟,鄢仁祥.基因芯片与高通量测序技术的原理与应用的比较[J].中国生物化学与分子生物学报,2018,34(11): 1166-1174. [24] SCHNEIDER A K,NIEMEYER C M.DNA Surface Technology: from gene sensors to integrated systems for life and materials sciences [J].Angew Chem Int Ed Engl,2018,57(52): 16959-16967. [25] 周宏伟.Verigene基因芯片法检测与氯吡格雷代谢相关基因CYP2C19多态性[C].中华医学会(Chinese Medical Association),中华医学会微生物学与免疫学分会.中华医学会第十二次全国临床微生物学术年会暨第十一次全球华人临床微生物学与感染症学术年会论文汇编.北京:中华医学会(Chinese Medical Association),中华医学会微生物学与免疫学分会,2015:1. [26] FEREIDOUNI M,MOOSSAVI M,KAZEMI T,et al.Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city,Iran [J].J Cell Biochem,2019,120(6): 9588-9593. [27] 石佳,贾佳,李国福.危重症患者静脉血栓栓塞症风险评估及预防研究进展[J].中国实用内科杂志,2019,39(2):185-188. |